EP1608642A1

EP1608642A1 - Enantioselective hydrogenation of intermediates during tipranavir synthesis

Info

Publication number: EP1608642A1
Application number: EP04721858A
Authority: EP
Inventors: Franz Dietrich Klingler; Michael Steigerwald; Richard Ehlenz
Original assignee: Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH and Co KG
Current assignee: Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH and Co KG
Priority date: 2003-03-24
Filing date: 2004-03-19
Publication date: 2005-12-28
Also published as: WO2004085427A1; CA2520129A1; DE10313118A1; US7002017B2; JP2006520748A; US20040224990A1

Abstract

The invention relates to a method for producing the compounds of general formula (I) by the enantioselective hydrogenation of compounds of formula (II) in the presence of special hydrogenation catalysts. The invention is characterised by a high enantioselectivity, enabling a substance class of important medicaments to be obtained in a simple manner.

Description

ENANTIOSELECTIVE HYDRATION OF INTERMEDIATES AT THE

Tipranavir SYNTHESIS

The present invention relates to a process for the preparation of intermediates in tipranavir synthesis, in particular an enantioselective hydrogenation. Intermediates which serve as starting compounds for the production of pharmaceutically active compounds are easily accessible via this process.

Background of the Invention

Chirality plays a crucial role in many biological processes and has also become increasingly important for the pharmaceutical industry, which is shown, for example, by the fact that over 80% of the drugs currently being developed have chiral properties. The different enantiomers can have completely different effects in the organism, so that only one of the enantiomeric forms is effective and is administered. In the organism, for example, enzymes whose chiral building blocks represent the amino acids can differentiate between the individual enantiomeric forms.

In particular, the enantiomers of 5,6-dihydro-4-hydroxy-2-pyrone are important structural elements in a large number of pharmaceutically active compounds, the class of 5,6-dihydro-4-hydroxy-2-pyrone-sulfonamides being of particular importance are. So it is with [R- (R *, R = ^!:) ] - N- [3- [l- [5,6-dihydro-4-hydroxy-2-oxo-6- (2-phenylethyl ) -6-propyl -2H-pyran-3-yl] propyl] phenyl] -5- (trifluoromethyl) -2-pyridinesulfonamide, known as tipranavir (PNU-140690), a protease inhibitor used to treat HIV Disease is used and has the following structure:

These as well as other structurally similar compounds are known from the prior art (see for example /. Med. Chem. 1998, 41, 3467-3476). In order to provide active ingredients that are as optically isomer-pure as possible, especially with regard to the above connecting group, the development of selective syntheses is essential. This results in a large number of processes for the production of chiral compounds, for example separation processes, such as crystallization or chromatographic processes.

A non-selective synthesis requires an additional separation step of the optical isomers, for example in the form of a final racemate resolution of the two enantiomers either by chemical or enzymatic means. It is therefore clear that selective syntheses that lead to only one optical isomer (either enantiomer or diastereomer) are advantageous. Thus, so-called asymmetric synthesis is increasingly used, i.e. only one optical isomer is preferably formed during a reaction. Enantio- or diastereoselective reactions are used not only in laboratory-scale syntheses, but also increasingly on an industrial scale.

A particularly elegant variant, preferably to synthesize an optical isomer, is enantio- or diastereoselective catalysis with chiral catalysts. The catalysts are transition metal complexes with one or more chiral ligands. The number of possible chiral ligands is almost unmanageable, and a large number of combinations of metal and ligand (s) are therefore opened. This range of variation also makes it difficult to find the best combination for the product to be manufactured in a simple manner.

The development of new ligand systems is of enormous interest, especially with regard to the industrial scale, according to which the economic requirements, such as efficient, cost-effective availability and high performance in terms of selectivity, yield and variability, should be met.

Asymmetric catalysis is important for a number of industrial processes and is used, among other things, for the production of amino acids, chiral amines and for ketone reduction. For example, Degussa has developed the DeguPhos catalyst, which is used for the reductive amination of alpha-keto acids to produce L- and D-amino acids. For the asymmetric hydrolysis of Amino acids are known to use DuPhos ([(l, 5-cyclooctadiene) rhodium (I) -l, 2- bis ((2R, 5R) -dimethyl-phospholano) benzene] tetrafluoroborate).

In addition, asymmetric hydrogenation as a chiral reaction is becoming increasingly important. Some asymmetric hydrogenations are known on a laboratory scale for the preparation of small quantities, but there are hardly any large-scale industrial processes that are used. For the transfer of such reactions on an industrial scale, it is necessary that the hydrogenation catalysts, in particular their ligands, have high selectivity and activity in addition to availability.

Some proposals for enantioselective hydrogenation are known from the prior art: for example, the disclosure of WO 00/55150 describes a process for the asymmetric hydrogenation of double bonds. Various intermediates for tipranavir synthesis are produced, using a rhodium catalyst with a chiral ligand containing at least one phosphorus atom. DuPhos (1,2-bis ((2R, 5R) -dimethylphospholano) benzene) or BPE (1,2-bis ((2R, 5R) -dimethylphospholano) ethane) are preferably used as chiral ligands.

US Pat. Nos. 5,171,892, 5,532,395, or 5,559,267 describe the use of an enantioselective rhodium catalyst with DuPhos ligand, which is said to provide an enantioselective hydrogenation in the range of 70 to 89%.

Furthermore, the teaching of WO 99/12919 describes a process for the preparation of 4-hydroxy-2-oxo-pyran derivatives, including an enantioselective one

Hydrogenation with a DuPhos as ligand-containing catalyst is carried out.

However, the above-mentioned transition metal complexes of chiral phosphine ligands usually show an insufficient activity in such catalytic processes, combined with only moderate stereoselectivity, so that the use of stoichiometric amounts of chiral hydride reagents would often be preferable. Accordingly, there remains a need to develop a stereoselective hydrogenation catalyst that avoids these disadvantages.

The invention is therefore based on the object in further training of the prior art to provide a process which allows an enantio- or diastereoselective hydrogenation in high yields, with high enantio- or diastereoselectivity, with the least possible technical effort and high space-time yield. This process should also be able to be implemented on an industrial scale, ie inexpensively and therefore be carried out in an economical manner. Furthermore, in the compounds provided according to the invention, which are of central importance in the synthesis of the pharmaceutically active compounds mentioned above, the chiral information contained in the starting compounds should not be lost during the hydrogenation and other groups present in the molecule should not be attacked by the hydrogenation , A process according to the invention is thus to be made available, with which selectively only a certain double bond is selectively hydrogenated to give only one optical isomer if possible.

Detailed Description of the Invention Surprisingly, it has been found that the above object of the present invention is achieved by a process for the preparation of the compounds of the general formula I:

wherein

R ¹ and R ² independently represent hydrogen or a radical which is selected from the group consisting of Ci-C _ό alkyl, C ₃ -C ₈ cycloalkyl, C ₆ -C ₁₀ aryl, and C ^ alkylene -Ce-o-aryl, optionally with one, two or three substituents, selected from the group consisting of OH, NH ₂ , NH-CO-CH ₃ or N (-CO-CH ₃ ) ₂ , halogen, -Gi- Alkoxy and CF ₃ , where R ¹ and R ² do not have the same meaning at the same time;

R ^{3 represents} an aryl which is substituted in the meta position and optionally has at least one further substituent, the substituents being selected from the group consisting of F, Cl, Br, I, OH, O-SO ₂ -CF ₃ , NO ₂ , NH ₂ , NH-SO ₂ - (4-trifluoromethylpyridin-2-yl), N (-CH ₂ -aryl) ₂ , NY! Y ₂ with Yi and Y ₂ selected from H, COO-alkyl, COO- CH ₂ aryl, CO alkyl, and CO aryl;

R ^{4 is} selected from the group consisting of H and Ca alkyl; and

R ^{5 is} selected from the group consisting of H, Si (CH ₃ ) ₃ , Li, Na, K, Cs,

* N (R ') ₄ , where all R' may be the same or different and are selected from Ci-Cβ-alkyl, and CH ₂ - aryl;

by hydrogenating the compounds of the general formula II:

R ² formula n

wherein the radicals R ¹ to R ^{5 can have} the meanings given above, in

Presence of a catalyst which has at least one ligand in the form of a chiral 1,2-bis (phospholano) maleic anhydride.

The starting compounds of the general formula I are intermediates in the production of tipranavir and related products which are used as

Starting compounds are used for the production of pharmaceutically active compounds. Mixtures of E / Z isomers (based on the double bond to be hydrogenated) can be used, of which surprisingly only one isomer is then hydrogenated. A mixture of about 50% E and about 50% Z isomer is preferably used.

According to a preferred variant of the invention, in the general formula I and TJ, R ¹ and R ² can be selected independently of one another from the group consisting of methyl, ethyl, propyl, butyl, phenyl, benzyl, cyclohexyl, phenylethyl and phenylpropyl, optionally with a Substituents selected from the group consisting of Hydroxy, fluorine, chlorine, bromine, methoxy, ethoxy and CF ₃ . R ^{1 is} particularly preferably phenylethyl and R ^{2 is} propyl or R ^{1 is} propyl and R ^{2 is} phenylethyl.

1

According to an embodiment which is particularly preferred according to the invention, R and R are selected from phenylethyl and propyl, R represents optionally substituted phenyl with an NO ₂ group in the meta position, R ⁴ means methyl and R ⁵ means hydrogen. If there is a further substituent in addition to the meta substituent in R ³ , it is preferred that this is selected from F, Cl, Br, I, OH or O-SO ₂ -CFs _s

In the present invention, alkyl groups, even if they are part of other radicals, unless otherwise defined, are to be understood as meaning branched and unbranched alkyl groups having 1 to 4 carbon atoms. The following hydrocarbon radicals are mentioned as examples: methyl, ethyl, propyl, 1-methylethyl (Isopropyl), n-butyl, 2-methylpropyl (iso-butyl), 1-methylpropyl (sec-butyl), 1,1-dimethylethyl (tert-butyl). The definitions of propyl and butyl include the respective isomeric forms. If necessary, the common abbreviations Me for methyl, Et for ethyl, prop for propyl and but for butyl are also used for the alkyl groups mentioned above.

In the present case, branched and unbranched alkylene bridges with 1 to 4 carbon atoms are regarded as alkylene groups. Examples include: methylene, ethylene, propylene and butylene. Unless otherwise stated, the abovementioned designations propylene and butylene encompass all of the possible isomeric forms. Accordingly, the term propylene includes the isomeric bridges n-propylene, methylethylene and dimethylmethylene and the term butylene the isomeric bridges n-butylene, 1-methylpropylene, 2-methylpropylene, 1,1-dimethylethylene and 1,2-dimethylethylene.

According to the invention, the cycloalkyl group is intended to represent a saturated cyclic hydrocarbon radical having 3 to 8 carbon atoms. Cyclic hydrocarbons having 3 to 6 carbon atoms are preferred. Examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

Alk loxy, which may also be referred to as alkoxy, means within the scope of the invention a straight-chain or bonded via an oxygen atom branched alkyl group with 1 to 4 carbon atoms. The methoxy group is particularly preferred.

The term aryl stands for an aromatic ring system with 6 to 10 carbon atoms. Preferred aryl radicals are naphthyl and phenyl, with the phenyl radical being particularly preferred. Abbreviations may be used for naphthyl and for phenyl Ph. For the purposes of the invention, aryl-alkylene or alkylene-aryl are understood to mean aryl groups which are linked via an alkylene bridge, the definitions given above applying to alkylene groups and aryl groups. Unless otherwise defined, alkylene aryl groups preferred according to the invention are benzyl, 2-phenylethyl and 3-phenylpropyl.

Halogen in the context of the present invention represents fluorine, chlorine, bromine or iodine, with fluorine, chlorine and bromine being preferred, unless otherwise defined.

The starting compounds of the general formula I shown above are selectively hydrogenated enantio in the presence of a catalyst. It is known that the hydrogenation of a molecule is influenced by other centers of chirality present in the molecule. However, this is not the case with the present compounds of formula I. According to the invention, the catalyst is therefore of major importance in this enantioselective hydrogenation. This enables the synthesis of the compounds of the above formula I directly from the compounds of the formula II, without further intermediate steps or a complicated separation of the isomeric forms.

In this context, enantioselective hydrogenation should also include diastereoselective hydrogenation, since a further chiral center can be located in the compounds of general formula I. However, the person skilled in the art knows what is meant by this in the present case.

As explained above, the catalyst of the invention contains a transition metal ion such as rhodium (I), ruthenium (I), iridium (I) or another suitable transition metal, with rhodium (I) preferably being present. This transition metal is coordinated with at least one ligand in the form of a chiral 1,2-bis (ρhospholano) maleic anhydride. According to the present invention, this 1,2-bis (phospholano) maleic anhydride should particularly preferably be understood to mean the system of the general formula III

wherein R ^L1 and R ^{L2 are} identical or different branched ess ooddeerr and branched C ₁ -C ₈ alkyl, preferably C ₁ -C 4 alkyl, particularly preferably methyl, ethyl or isopropyl.

According to the invention, particular preference is given to a system of the formula III in which R ^L1 and R ^{L2 have} the same meanings, particularly preferably both methyl. The last preferred compound of the formula III, in which ^' R ^L1 and R ² both denote methyl, is also known under the name MalPhos in the prior art.

The chiral 1,2-bis (phospholano) maleic anhydride presented above represents an optionally substituted bidentate bisphospholane system, i.e. Two five-membered saturated rings, each with a phosphorus atom in the ring - the so-called phospholane systems - are bonded to the double bond of a maleic anhydride via the two phosphorus atoms. Such ligands are known under the trade name MalPhos. The transition metal forms a complex with the ligand, which can be used as a hydrogenation catalyst.

According to a further preferred embodiment, the catalyst has the following structure:

[Ligand ^ transition metal ligand ² ] anion,

wherein the ligand ^{1 means} the chiral 1,2-bis (phospholano) maleic anhydride of the formula EU shown above. Ligand ² is preferably an unsaturated cyclic hydrocarbon having 3 to 12 carbon atoms, cyclopentadiene, benzene, cyccloheptatriene or cyclooctadiene systems being preferably used. ² cyclopentadiene or 1,5-cyclooctadiene (COD) is particularly preferably used as a ligand. Ligand ² can be substituted with one or more organic groups. In a preferred embodiment according to the invention, ligand ^{2 is} unsubstituted. If the ligand ^{2 is} substituted on the other hand, linear or branched Ci-Cβ-alkyl groups, in particular C ₁ -C ₄ -alkyl groups, are suitable as substituents. In the catalyst used according to the invention there is preferably an anion as counterion to the transition metal cation complex, such as BF ₄ ^" , CF3-CO-O ^" , Cl ^" , Br ^" or I ^" , of which the BF ₄ ^" adduct is preferred.

The hydrogenation catalyst which is particularly preferred in the process according to the invention, the MalPhos-Rhodium-l, 5-cycclooctadiene-tetrafluoroborane adduct, is shown below:

As is known, the enantioselectivity of the hydrogenation is used by the

Catalyst influenced, but predictions about structure-activity relationships in such complex systems are only possible in a few individual cases. In the development of chiral ligands that can be used in such complexes, the steric conditions play a role, such as a certain conformational rigidity of the complex. In addition to the steric parameters of the phospholanes, which, together with the ligand backbone, determine the overall structure and determine the geometry of the metal binding site, the electronic properties of the donor atoms (σ- / π-donor / acceptor capacity) are a second parameter, which significantly determines the properties of catalytically active transition metal complexes determine. Furthermore, the overall electronic character of the ligand appears to be important. It is indeed possible to fine-tune the conformational, steric and electronic properties of the ligands with considerable effort, but due to the numerous different influences, it is not easy to draw a systematic conclusion about the effectiveness and usefulness of a particular catalyst.

In addition to the chemical and physical properties of the ligands, the costs for the transition metal and the ligands and the activity and stability of the catalyst also play a role, and the possibility of recovering them and reusing them after appropriate processing. Catalysts are also not readily commercially available and must first be prepared using complex processes. These considerations are particularly relevant for large-scale processes.

Based on the above findings, a very large number of attempts have been made to find a catalytic system that meets the desired requirements to a high degree. According to the invention, it has been possible to use a hydrogenation catalyst in the process provided which not only has excellent activity and stability and is inexpensive to produce, but also leads to the desired products in a highly enantioselective manner. Thus, an enantioselective hydrogenation in the range of over about 90%, preferably over about 95%, particularly preferably over about 98% is achieved by the process according to the invention.

The method according to the invention is to be explained in detail below:

The starting compounds according to the general formula I above are intermediates on the way to tipranavir synthesis, which can be processed further after the enantioselective hydrogenation has taken place. The starting compound of the formula I can be used either in the form of an isomer or as a mixture of E and Z isomers.

Some substituents require that the hydrogenation be carried out in the presence of a base. This is the case, for example, when R ^{5 represents} a hydrogen atom or an Si (CH ₃ ) ₃ group. This represents general knowledge of the person skilled in the art who knows when the use of an appropriate base is necessary. The base is preferably selected from the group consisting of a hydroxide, C ₁ -C 5 alkoxide, bicarbonate, carbonate, di- and tribasic phosphate, borate, fluoride, optionally amine substituted with C ₁ -C ₄ alkyl or aryl, optionally with C ₁ -C ₃ alkyl substituted silane. The base is particularly preferably an alkali or alkaline earth metal methanolate, ethanolate or carbonate, particularly preferably a carbonate. Particularly preferred alkali or alkaline earth alcoholates or carbonates are those of sodium, potassium, calcium or magnesium, those of sodium and potassium, in particular sodium, being of outstanding importance according to the invention.

It has proven to be particularly advantageous if the base is used in an amount of about 1 mol% to about 20 mol%, preferably about 5 mol% to about 15 mol%.

It is expedient to carry out the hydrogenation under an inert gas atmosphere. Nitrogen gas or a noble gas such as argon are suitable for this, nitrogen being preferred for cost reasons.

The hydrogenation according to the invention is advantageously carried out in a solvent. According to the invention, the solvents conventionally used for hydrogenation reactions can be used as solvents. Examples include: methanol, ethanol, acetone, methylene chloride, ethyl acetate, toluene, xylene and acetonitrile. Methanol and ethanol are particularly preferably used as solvents.

It has turned out to be particularly advantageous if the catalyst is added last to the reaction mixture. However, this is not always necessary. The amount of catalyst used is preferably about 0.001 mol% to about 5 mol%, preferably about 0.01 mol% to about 0.5 mol%, in particular about 0.05 mol% to about 0.15 mol%. This results in the ratio (in moles) of substrate / catalyst of about 200/1 to 5000/1, preferably about 500/1 to about 3000/1, in particular about 1000/1 to about 2000/1.

According to a preferred embodiment, the catalyst is first dispersed or dissolved in a solvent and then added to the reaction mixture containing the compound to be hydrogenated, solvent and optionally a base. The same is then preferred for the catalyst and the reaction mixture Solvent used. The catalyst can also be added without a solvent.

After or during the addition of the catalyst, the hydrogenation is started. The hydrogenation according to the process of the invention is preferably carried out in one

Temperature interval from about 20 ° C to about 100 ° C, preferably about 40 ° C to about 80 ° C, particularly preferably between about 50 ° C and about 70 ° C, most preferably at about 60 ° C. It is recommended to _{'ώιsbesondere} when delicate Rektionsgruppen in the molecule, that the temperature is about 100 ° C, in some cases, about 80 ° C does not exceed. For example, a nitro group present in the molecule is reduced to the amino group at temperatures above about 80 ° C, which can be undesirable. Temperatures below about 20 ° C slow the reaction so that this is no longer of economic interest.

Within the scope of the hydrogenation according to the invention, the level of the set pressure is not particularly limited. This essentially serves to increase the reaction rate. However, it is expedient to set the hydrogen pressure in the hydrogenation in the range from approximately 2 bar to approximately 200 bar, preferably approximately 10 bar to approximately 50 bar, particularly preferably between approximately 15 bar and approximately 40 bar.

The hydrogenation according to the invention is preferably carried out for a reaction time of about 1h to about 100h, particularly preferably about 5h to about 40h, particularly preferably about 10h to about 30h. According to the invention, it is therefore possible, with a relatively short reaction time of about 24 hours, to achieve an enantioselectivity of over about 90%, preferably over about 95%, in particular even over 98%. This shows the clear superiority over the systems known to date in the prior art, which do not show this selectivity to this extent.

The hydrogenated product obtained can be subjected to an additional purification, for example one or more washing steps and / or recrystallization in the solvent used, and can be separated off and worked up in a conventional manner.

It is readily possible for the person skilled in the art to determine the most suitable reaction conditions, such as temperature, pressure, solvent, reaction time and to select and adjust the same for the respective hydrogenation and to optimize it accordingly on the basis of less orientated experiments.

The advantages associated with the invention are multifaceted: the process according to the invention enables easy access to isomers which have hitherto been relatively difficult to access, which is also possible on an industrial scale with excellent productivity. The process according to the invention makes it possible to provide the desired product not only in high yields but also with very high enantioselectivity. No additional cleaning steps are required, the products can be processed directly as they are.

The hydrogenation catalyst used according to the invention has a high performance, in particular in the form of excellent activity and stability, and is highly enantioselective, so that the desired products can be obtained in a simple manner. According to the method according to the invention, a

Enantioselectivity in the range above about 90%, preferably above about 95%, particularly preferably above about 98%. Starting from the E / Z isomer mixture, a complex separation into the two isomers can thus be avoided; rather, only the desired isomer is obtained in hydrogenated form, this not only working on a laboratory scale, but also in large-scale industrial plants.

The economic requirements for large-scale use, such as high performance in terms of selectivity, yield and variability, are thus largely met by the catalyst according to the invention. In addition, the catalysts used in the hydrogenation process of the invention are inexpensive to manufacture. The starting products for the production of MalPhos are significantly cheaper compared to the starting materials for DuPhos, so that the production of the catalyst is much cheaper.

The efficiency of the catalyst system used according to the invention is also clearly superior to that of the prior art. For example, reactions catalyzed with rhodium-malphos systems run faster and with higher enantioselectivity compared to the corresponding DuPhos systems. According to the invention, easy access to a substance class of important medicinal products is therefore possible, the non-peptide HJV protease inhibitors, such as tipranavir, so that the technical teaching of the invention is a valuable enrichment for the pharmaceutical sector.

The invention is described in detail below using an example which is not intended to limit the teaching according to the invention. Further exemplary embodiments are obvious to the person skilled in the art in the context of the disclosure according to the invention. ^is -

Example 1:

An enantioselective hydrogenation according to the invention was carried out starting from the following compound 1:

Compound 1 disereoselectively hydrogenated compound 1 MW = 421.50 MW = 423.51 molecular formula C sH ₂ NOs molecular formula: C25H29NO5

The hydrogenation was carried out as follows:

67 g of compound 1, 270 ml of methanol and 1.7 g of sodium carbonate were placed in a 500 ml autoclave. After complete inertization, a solution of 96.8 mg of Malphos- [Rh (COD)] - BF ₄ in 10 ml of degassed methanol was added under nitrogen. The mixture was then stirred at about 60 ° C and about 10 bar hydrogen pressure for about 24 h.

The hydrogenation solution was rinsed with 14 ml of methanol in a glass reactor, warmed to about 50 ° C. and adjusted to a pH of about 1.4 with hydrochloric acid (32%). 61 ml of water were added dropwise at about 50 ° C. over 2 hours. The mixture was then at 20 ° C for 3 h cooled, stirred at this temperature for 1.5 h and finally the crystalline product was suction filtered. It was washed with 133 ml of methanol / water (2: 1) and dried at about 45 ° C. i.vac, which gave about 50.5 g (about 80%) of the hydrogenated compound 1.

Chemical and optical purity:> 98% (1H-NMR).

Claims

claims

1. Process for the preparation of the compounds of the general formula I:

R ² formula I.

1 wherein R and R independently of one another represent hydrogen or a radical which is selected from the group consisting of d-Cό-alkyl, C ₃ -C ₈ cycloalkyl, Cό- o- aryl, and -CVAlkylen-Ce- o- Aryl, optionally with one, two or three

Substituents selected from the group consisting of OH, NH ₂ , NH-CO-CH ₃ or N (- CO-CH ₃ ) ₂ , halogen, dC -alkoxy and CF ₃ , where R and R do not have the same meaning at the same time;

R ^{3 represents} an aryl substituted in the meta position, which optionally has at least one further substituent, the substituents being selected from the group consisting of F, Cl, Br, I, OH, O-SO ₂ -CF ₃ , NO ₂ , NH ₂ , NH-SO ₂ - (4-trifluoromethylpyridin-2-yl), N (-CH ₂ -aryl) ₂ , NY1Y2 with Yi and Y ₂ selected from H, COO-alkyl, COO-CH ₂ -aryl , CO-alkyl and CO-aryl;

R) 4 is selected from the group consisting of H and -Cs alkyl; and

R ^{5 is} selected from the group consisting of H, Si (CH ₃ ) ₃ , Li, Na, K, Cs, N (R '), where all R' may be the same or different and are selected from d-Cs- Alkyl and CH ₂ aryl;

by hydrogenating the compounds of the general formula II:

R ² formula n in which the radicals R ¹ to R ⁵ can have the meanings given above, in the presence of a catalyst which has at least one ligand in the form of a chiral 1, 2-bis (phospholano) maleic anhydride.

2. The method according to claim 1, characterized in that R 1 and R 9 are independently selected from the group consisting of methyl, ethyl, propyl, butyl, phenyl, benzyl, cyclohexyl, phenylethyl and phenylpropyl, optionally with a substituent, selected from the group consisting of hydroxy, fluorine, chlorine, bromine, methoxy, ethoxy and CF ₃ .

3. The method according to any one of claims 1 or 2, characterized in that R ^{1 is} phenylethyl and R ² propyl or R ¹ propyl and R ^{2 are} phenylethyl.

4. The method according to any one of claims 1 to 3, characterized in that R ¹ and R are selected from phenylethyl and propyl, R is optionally substituted phenyl with a Nθ ₂ group in the meta position, R ^{4 is} methyl and R ^{5 is} hydrogen ,

5. The method according to at least one of the preceding claims, characterized in that the starting compounds of the general formula I are used in the form of a Z- / E mixture.

6. The method according to claim 5, characterized in that an approximately 50:50 mixture of E and Z isomer is used.

7. The method according to at least one of the preceding claims, characterized in that the catalyst has the following structure:

(Ligand ¹ transition metal ligand ² ] anion,

wherein the ligand ^{1 is} a chiral 1,2-bis (phospholano) maleic anhydride of the formula III

wherein R ^L1 and R ^{L2 represent the} same or different branched or unbranched Ci-Q-alkyl.

8. The method according to claim 7, characterized in that the ligand ^{2 is} an unsaturated cyclic hydrocarbon having 3 to 12 carbon atoms.

9. The method according to claim 7 or 8, characterized in that the ligand ^{2 is} a cyclopentadiene, benzene, cycloheptatriene or cyclooctadiene system.

10. The method according to claim 9, characterized in that the ligand is cyclopentadiene or 1,5-cyclooctadiene.

11. The method according to at least one of claims 7 to 10, characterized in that in ligand ^{1 of} the formula IQ, R ¹ and R ^{2 are} branched or unbranched C ₁ -C ₄ alkyl, preferably methyl, ethyl or isopropyl.

12. The method according to claim 11, characterized in that R ^L1 and R ^L2 both mean methyl.

13. The method according to at least one of the preceding claims, characterized in that the transition metal in the catalyst is rhodium (I), ruthenium (I) or iridium (I).

14. The method according to at least one of the preceding claims, characterized in that the anion in the catalyst is BF ₄ ^" , CF ₃ -CO-O ^" , Cl ^" , Br ^" or I ^" .

15. The method according to at least one of the preceding claims, characterized in that it is carried out in the presence of the following catalyst:

16. The method according to at least one of the preceding claims, characterized in that the hydrogenation is carried out in the presence of a base.

17. The method according to claim 16, characterized in that the base is selected from the group consisting of a hydroxide, Q-Cs alkoxide, bicarbonate, carbonate, di- and tribasic phosphate, borate, fluoride, optionally with C 1 -C ₄ -Alkyl or aryl-substituted amine, optionally substituted with -C-C ₃ alkyl-substituted silane.

18. The method according to claim 16 or 17, characterized in that the base is selected from alkali or alkaline earth metal methoxide, ethanolate or carbonate.

19. The method according to any one of claims 16 to 18, characterized in that the base is used in an amount of about 1 mol% to about 20 mol%, preferably about 5 mol% to about 15 mol%.

20. The method according to at least one of the preceding claims, characterized in that the ratio (in mol) of substrate / catalyst is about 200/1 to 5000/1, preferably about 500/1 to about 3000/1.

21. The method according to at least one of the preceding claims, characterized in that the temperature in the hydrogenation is about 20 ° C to about 100 ° C, preferably about 50 ° C to about 70 ° C.

22. The method according to at least one of the preceding claims, characterized in that the hydrogen pressure in the hydrogenation is about 2 bar to about 100 bar, preferably about 10 bar to about 50 bar.